Ventricular premature contractions associated with iloperidone

Achalia, Rashmin; Andrade, Chittaranjan

doi:10.4103/0019-5545.111464

Cited by 5 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 17 Finally, a 29-year-old male taking iloperidone (16 mg/day) developed palpitations and was diagnosed with premature ventricular contractions. 19 Symptoms in all these cases resolved after stopping iloperidone and switching to alternate therapies.…”

Section: Safety and Tolerabilitymentioning

confidence: 96%

“…Freeman reported two cases of retrograde ejaculation in two young males (aged 21 and 24 years) with schizophrenia after taking iloperidone (8 mg twice daily) for 2 or 3 weeks 17. Finally, a 29-year-old male taking iloperidone (16 mg/day) developed palpitations and was diagnosed with premature ventricular contractions 19. Symptoms in all these cases resolved after stopping iloperidone and switching to alternate therapies.…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

See 1 more Smart Citation

Long-term efficacy and safety of iloperidone: an update

Rado¹,

Janicak²

2014

NDT

View full text Add to dashboard Cite

Schizophrenia is a devastating neuropsychiatric disease with a worldwide prevalence of approximately 0.5%–1%. Since many patients do not achieve adequate symptom relief from available agents, alternate pharmacotherapeutic approaches are needed. In this context, iloperidone was recently approved by the US Food and Drug Administration for the treatment of schizophrenia. This paper first reviews its pharmacodynamic and pharmacokinetic profiles, emphasizing their clinical relevance. Next, it summarizes the literature on its acute and maintenance efficacy, safety, and tolerability. It then considers pharmacogenetic data which may help to predict response and risk of cardiac arrhythmias with this agent. Finally, it critically positions iloperidone relative to other first- and second-generation antipsychotics.

show abstract

Section: Safety and Tolerabilitymentioning

confidence: 96%

Section: Safety and Tolerabilitymentioning

confidence: 99%

Long-term efficacy and safety of iloperidone: an update

Rado¹,

Janicak²

2014

NDT

View full text Add to dashboard Cite

show abstract

“…Although no cases of iloperidone-associated sudden death due to arrhythmias have been reported, avoidance of this drug may be prudent for patients who are medically susceptible to heart diseases or for patients taking concomitant medications that lengthen the QT interval. These precautions are similar to those for ziprasidone 39,40,59. So far, only one case of ventricular premature contractions has been published and is possibly related to iloperidone inducing alpha 2c receptor blockage 59…”

Section: Resultsmentioning

confidence: 81%

“…Concomitant medications must be closely monitored; the dose of iloperidone needs to be reduced in the presence of other drugs, especially drugs that are strong CYP450 inhibitors 53,59,61. So far, no evidence on iloperidone causing acute kidney injury (AKI) is available.…”

Section: Resultsmentioning

confidence: 99%

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy

Tonin¹,

Wiens²,

Fernández-Llimós³

et al. 2016

View full text Add to dashboard Cite

IntroductionSchizophrenia is a chronic and debilitating mental disorder that affects the patient’s and their family’s quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as iloperidone, can provide more effective, tolerable and safer strategies.AimTo review the evidence for the clinical impact of iloperidone on the treatment of patients with schizophrenia.Evidence reviewClinical trials, observational studies and meta-analyses reached a common consensus that iloperidone is as effective as haloperidol, risperidone and ziprasidone in reducing schizophrenia symptoms. Similar amounts of adverse events and discontinuations were observed with iloperidone compared to placebo and active treatments. Common adverse events are mild and include dizziness, hypotension, dry mouth and weight gain. Iloperidone can induce extension of QTc interval, and clinicians should be aware of its contraindications. In long-term trials, iloperidone also showed promising safety and tolerability profiles. The low propensity to cause akathisia, extrapyramidal symptoms (EPS), increased prolactin levels or changes to metabolic laboratory parameters support its use in practice. Results showed that iloperidone prevents relapse in stabilized patients, with a time to relapse superior to placebo and similar to haloperidol. Patients using a prior antipsychotic (eg, risperidone and aripiprazole) can easily switch to iloperidone with no serious impact on safety or efficacy. However, the acquisition costs of iloperidone may hamper its use. Further evidence comparing iloperidone with other antipsychotics, and pharmacoeconomic studies would be welcome.Place in therapyConsidering just the clinical profile of iloperidone, it represents a promising drug for treating schizophrenia, particularly in patients who are intolerant to previous antipsychotics, as well as being suitable as first-line therapy. Cost-effectiveness comparisons are needed to justify its use in clinical practice.

show abstract

Iloperidone-induced urinary incontinence in a female patient with schizophrenia: A case report

Arafat¹

2020

Neurology, Psychiatry and Brain Research

View full text Add to dashboard Cite

Ventricular premature contractions associated with iloperidone

Cited by 5 publications

References 8 publications

Long-term efficacy and safety of iloperidone: an update

Long-term efficacy and safety of iloperidone: an update

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy

Iloperidone-induced urinary incontinence in a female patient with schizophrenia: A case report

Contact Info

Product

Resources

About